All relevant data are within the paper.

Introduction {#sec005}
============

Treatment with an anticoagulant in patients with atrial fibrillation (AF) decreases the risk of cerebral infarction; the challenge consists of balancing between protection against thromboembolic diseases and complications of bleeding, and risk scores have been under development for almost 20 years \[[@pone.0176846.ref001]--[@pone.0176846.ref003]\]. Guidelines recommend the CHA~2~DS~2~-VASc score, which is the most commonly used risk score in clinical practice today \[[@pone.0176846.ref003]--[@pone.0176846.ref004]\]. According to the CHA~2~DS~2~-VASc score, anticoagulant therapy is recommended or considered for patients with 2 or more points while those with a 0 point should not be treated \[[@pone.0176846.ref003]\]. However, the 1 point group constitutes a gray zone with a reported annual incidence of stroke and transient ischemic attack (TIA) between 0.2% and 6.6% in different studies \[[@pone.0176846.ref005]--[@pone.0176846.ref011]\]. Some studies have indicated that, among patients with AF and 1 point in the CHA~2~DS~2~-VASc score, an age between 65 and 74 years is at the highest risk for stroke and TIA \[[@pone.0176846.ref005],[@pone.0176846.ref008],[@pone.0176846.ref012]\]. Our aim was, in a nationwide cohort of patients with incident AF with and without warfarin therapy, to compare the risks of cerebral infarction and stroke according to CHA~2~DS~2~-VASc score, age and sex.

Materials and methods {#sec006}
=====================

We conducted a nationwide, retrospective cohort study using the Swedish National Patient Registry, the National Prescribed Drugs Registry, the Swedish Register of Education and the Population and Housing Census Registry, and the study cohort was identified by the epidemiological centre at the Swedish National Board of Health and Welfare and Statistics Sweden. The Swedish National Patient Registry has a \>99% coverage of hospital diagnoses from 1987 and onwards, and the diagnoses have a positive predictive value of 85--95% \[[@pone.0176846.ref013]\]. The validity of the registry is high and has therefore been recommended for use in epidemiological studies by the National Board of Health and Welfare \[[@pone.0176846.ref013]--[@pone.0176846.ref014]\]. Information about medication was obtained from the National Prescribed Drugs Registry, which started 1 July 2005. To increase the probability that patients did not take warfarin before the study period began, we applied a washout period between 1 July 2005 and six months afterwards. Thus, patients with incident AF between 1 January 2006 and 31 December 2008 were eligible. AF was defined according to the International Classification of Diseases (ICD): 427 D (DA, DB, DC, DD, DW) in ICD 9 (1987--1996) and I 48, I48.9 and I 48.9 (A, B, C, D, E, F, P, X) in ICD 10 (1997-). According to the CHA~2~DS~2~-VASc score, patients could receive a maximum of 9 points: age 65 to 74 years (1 point) and ≥75 years (2 points), female sex (1 point) and diagnoses from ICD 9 and ICD 10: congestive heart failure 428 and I 50 (1 point), hypertension 401--405 and I 10--14 (1 point), diabetes mellitus 250 and E 10--14 (1 point), cerebral infarction 433--434 and I 63--64 (2 points), TIA 435 and G 45 (2 points) and vascular disease 410--414, 440, 443.9 and I 20--25, I 70, I 73.9 (1 point) from 1987 and until 30 days after the date of diagnosis of incident AF. The educational background was obtained from the Swedish Register of Education and the Population and Housing Census Registry by Statistics Sweden.

Warfarin was the only registered oral anticoagulant in Sweden during our study period, and phenprocoumon could be prescribed \[[@pone.0176846.ref005]\]. During the years of this study, acetylsalicylic acid (ASA) was recommended for patients with 0 and 1 point based on the CHADS~2~ score \[[@pone.0176846.ref001]\]. Recent studies do not support ASA in patients with AF, and current guidelines do not recommend it for protection of cerebral infarction; we therefore did not consider ASA to be analyzed \[[@pone.0176846.ref003],[@pone.0176846.ref015],[@pone.0176846.ref016]\].

In Sweden, all inhabitants have a unique personal identification number, all have equal access to health care and hospital services, and hospitals are required to record all discharge diagnoses. This provides the possibility to record and track all non-emigrated patients in clinical registries and examine morbidity and mortality in the entire Swedish population. This study complied with the Declaration of Helsinki, and the study protocol was approved by the Regional Ethical Review Board in Uppsala, Sweden (Dnr 2009/273).

Study cohort {#sec007}
------------

In total, there were 272 186 patients with incident AF between 1987 and 2008 and, of those, 59 981 had a diagnosis of AF during the inclusion period between 1 January 2006 and 31 December 2008 ([Fig 1](#pone.0176846.g001){ref-type="fig"}). We excluded 11 548 patients who had warfarin before the diagnosis of AF or had died, emigrated or suffered a stroke within 30 days after diagnosis. The remaining 48 433 patients were categorized into three groups: 1) warfarin treatment started within 30 days and regular withdrawal, 2) no warfarin and 3) warfarin treatment started after 30 days or more or irregular withdrawal. These groups consisted of 15 782, 27 166 and 5 485 patients, respectively ([Table 1](#pone.0176846.t001){ref-type="table"}). Our definition of regular withdrawal was that warfarin had been collected at a pharmacy at least once a year after the date of incident AF. Over- and under-treatment are well known, and some patients were treated regularly with warfarin contrary to contemporary guidelines \[[@pone.0176846.ref017]\]. Although treatment should be started instantly when the indication is clear, we applied a cut-off at 30 days so that the necessary diagnostics, for example echocardiography or newly discovered diabetes mellitus, were completed to determine the CHA~2~DS~2~-VASc score.

![Flowchart.\
All patients were followed until an event of cerebral infarction, stroke, death, emigration or end of study at 31 December 2009. Patients in warfarin/no warfarin could belong to both the exposed and non-exposed arm. ^a^Patients received warfarin after 30 days or more from incident atrial fibrillation or irregular withdrawal during the study period or until occurrence of an endpoint.](pone.0176846.g001){#pone.0176846.g001}

10.1371/journal.pone.0176846.t001

###### Baseline characteristics.

![](pone.0176846.t001){#pone.0176846.t001g}

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                        1.Warfarin         2.No warfarin      3.Warfarin/\                                        Total
                                                                                                                              No warfarin[^a^](#t001fn002){ref-type="table-fn"}   
  ------------------------------------------------------------------------------------- ------------------ ------------------ --------------------------------------------------- ------------------
  **Patients**[^b^](#t001fn003){ref-type="table-fn"}                                    15 782 (42.4)      27 166 (45.1)      5 485 (45.6)                                        48 433 (44.3)

  **Age (years)**                                                                                                                                                                 

  Mean±SD                                                                               71.5±9.7           71.7±12.5          70.7±10.2                                           71.5±11.4

  Women mean±SD                                                                         74.1±8.2           74.4±10.8          73.0±9.1                                            74.1±9.8

  Men mean±SD                                                                           69.5±10.3          69.5±13.4          68.8±10.7                                           69.5±12.1

  **Year, diagnosis of AF**                                                                                                                                                       

  2006                                                                                  4 646              8 952              2 315                                               15 913

  2007                                                                                  5 304              8 990              1 838                                               16 130

  2008                                                                                  5 834              9 224              1 332                                               16 390

  **Age categories**[^b^](#t001fn003){ref-type="table-fn"}                                                                                                                        

  \<65 years                                                                            3 610 (23.9)       6 551 (24.1)       1 374 (25.1)                                        11 535 (23.8)

  65--74 years                                                                          5 055 (32.0)       6 315 (23.2)       1 787 (32.6)                                        13 157 (27.2)

  75--85 years                                                                          7 117 (45.1)       14 300 (52.6)      2 324 (42.4)                                        23 741 (49.0)

  **CHA**~**2**~**DS**~**2**~**-VASc score**[^c^](#t001fn004){ref-type="table-fn"}                                                                                                

  0                                                                                     1 005 (6.4)        2 547 (9.4)        421 (7.7)                                           3 973 (8.2)

  1                                                                                     1 885 (11.9)       3 251 (12.0)       798 (14.5)                                          5 934 (12.3)

  2                                                                                     2 855 (18.1)       4 369 (16.1)       1 065 (19.4)                                        8 289 (17.1)

  ≥3                                                                                    10 037 (63.6)      16 999 (62.6)      3 201 (58.4)                                        30 237 (62.4)

  *3*                                                                                   *3 369 (21*.*4)*   *5 374 (19*.*8)*   *1 202 (21*.*9)*                                    *9 945 (20*.*5)*

  *4*                                                                                   *3 069 (19*.*3)*   *4 945 (18*.*2)*   *1 018 (18*.*6)*                                    *9 032 (18*.*6)*

  *5*                                                                                   *2 050 (13*.*0)*   *3 410 (12*.*6)*   *547 (10*.*0)*                                      *6 007 (12*.*4)*

  *6*                                                                                   *1 046 (6*.*6)*    *2 056 (7*.*6)*    *293 (5*.*3)*                                       *3 395 (7*.*0)*

  *7*                                                                                   *398 (2*.*5)*      *878 (3*.*2)*      *108 (2*.*0)*                                       *1 384 (2*.*9)*

  *8*                                                                                   *90 (0*.*6)*       *276 (1*.*0)*      *30 (0*.*5)*                                        *396 (0*.*8)*

  *9*                                                                                   *15 (0*.*1)*       *60 (0*.*2)*       *3 (0*.*1)*                                         *78 (0*.*2)*

  **CHA**~**2**~**DS**~**2**~**-VASc diseases**[^c^](#t001fn004){ref-type="table-fn"}                                                                                             

  Hypertension                                                                          7 091 (44.9)       11 588 (42.7)      2 411 (44.0)                                        21 090 (43.5)

  Ischemic heart disease                                                                4 300 (27.2)       8 925 (32.9)       1 687 (30.8)                                        14 912 (30.8)

  Heart failure                                                                         4 446 (28.2)       5 559 (20.5)       1 035 (18.9)                                        11 040 (22.8)

  Diabetes mellitus                                                                     2 303 (14.6)       4 474 (16.5)       783 (14.3)                                          7 560 (15.6)

  Myocardial infarction                                                                 1 914 (12.1)       4 542 (16.7)       858 (15.6)                                          7 314 (15.1)

  Stroke                                                                                2 231 (14.1)       3 305 (12.2)       466 (8.5)                                           6 002 (12.4)

  TIA                                                                                   906 (5.7)          1 019 (3.8)        185 (3.4)                                           2 110 (4.4)

  Atherosclerosis                                                                       287 (1.8)          785 (2.9)          110 (2.0)                                           1 182 (2.4)

  Vascular disease                                                                      175 (1.1)          394 (1.5)          74 (1.3)                                            643 (1.3)

  **Other diseases**[^c^](#t001fn004){ref-type="table-fn"}                                                                                                                        

  Tumores                                                                               2 291 (14.5)       7 150 (26.3)       988 (18.0)                                          10 429 (21.5)

  COPD                                                                                  909 (5.8)          2 236 (8.2)        324 (5.9)                                           3 469 (7.2)

  Chronic renal failure                                                                 235 (1.5)          869 (3.2)          115 (2.1)                                           1 219 (2.5)

  **Education**[^c^](#t001fn004){ref-type="table-fn"}                                                                                                                             

  1.Primary education \<9 years                                                         6 246 (39.6)       11 127 (41.0)      2 027 (37.0)                                        19 400 (40.1)

  2.Primary education ≥9 years                                                          1 201 (7.6)        2 034 (7.5)        419 (7.6)                                           3 654 (7.5)

  3.Upper secondary education \<3 years                                                 4 048 (25.6)       6 465 (23.8)       1 386 (25.3)                                        11 899 (24.6)

  4.Upper secondary education ≥3 years                                                  1 510 (9.6)        2 635 (9.7)        550 (10.0)                                          4 695 (9.7)

  5.Post-secondary education \<3 years                                                  1 083 (6.9)        1 830 (6.7)        443 (8.1)                                           3 356 (6.9)

  6.Post-secondary education ≥3 years                                                   1 349 (8.5)        2 235 (8.2)        524 (9.6)                                           4 108 (8.5)

  7.Post-graduate                                                                       98 (0.6)           201 (0.7)          49 (0.9)                                            348 (0.7)

  8.Unknown                                                                             247 (1.6)          639 (2.4)          87 (1.6)                                            973 (2.0)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SD indicates standard deviation; AF, atrial fibrillation; COPD, chronic obstructive pulmonary disease; and TIA, transitoric ischemic attack

^a^Patients received warfarin after 30 days or more from incident atrial fibrillation or irregular withdrawal during the study period until 2009-12-31 or occurrence of an endpoint

^b^Women in percent

^c^Proportion in percent

Time-varying exposure analysis {#sec008}
------------------------------

To include all eligible patients and to decrease the risk of treatment misclassification, we used time-varying exposure analysis. This means that patients with irregular warfarin treatment or who had started warfarin after 30 days or more from incident AF are included in both the exposed and non-exposed arms at different times depending on whether warfarin treatment is on-going ([Table 2](#pone.0176846.t002){ref-type="table"}). Patients with warfarin treatment started within 30 days of incident AF were analyzed in the exposed arm and those without warfarin in the non-exposed arm during the study period or until an endpoint.

10.1371/journal.pone.0176846.t002

###### Study groups and possible exposures to warfarin in the time-varying analysis.

![](pone.0176846.t002){#pone.0176846.t002g}

  Study groups                                               n        \%     Warfarin   No warfarin
  ---------------------------------------------------------- -------- ------ ---------- -------------
  1.Warfarin regularly and started within 30 days, exposed   15 782   32.6   X          
  2.No warfarin, non-exposed                                 27 166   56.1              X
  3.Warfarin irregularly or started after 30 days or more    5 485    11.3   X          X
  Total                                                      48 433   100               

In the time-varying analysis, patients with warfarin with irregular withdrawal or who started after 30 days or more are included in the exposed or non-exposed arms at different times depending on whether warfarin treatment was on-going.

Outcomes {#sec009}
--------

The primary outcome was a diagnosis of cerebral infarction and stroke. The classifications of diagnosis from the ICD 10 were: I 63 (0, 1, 2, 3, 4, 5, 6, 8, 9) and I 64. The secondary outcome was cerebral bleeding I 60-I 62. We used a quarantine period to reduce an overestimate of outcomes, and the follow-up began 30 days after the date of incident AF \[[@pone.0176846.ref007]\]. The follow-up time ended on the date of outcome, death, emigration or the end of the study on 31 December 2009, whichever occurred first.

Statistical analysis {#sec010}
--------------------

Continuous variables are presented as mean ± SD and categorical as percentages. Cox regression was used to evaluate the relative risk of cerebral infarction and stroke to warfarin treatment as a time-varying exposure, adjusted for potential confounders. Adjustment was made for age, year of AF diagnosis, sex, neoplasm (140--239 and C 00-D 48), chronic obstructive pulmonary diseases (COPD) (496 and J 44), chronic renal failure (585 and N 18) and education. Neoplasm, COPD and chronic renal failure affect mortality, and might also increase the risk of cerebral infarction and stroke, and education has been stated to be an important factor in life expectancy and prescription of oral anticoagulation; we therefore adjusted for this potential confounder \[[@pone.0176846.ref018]--[@pone.0176846.ref019]\]. All potential confounders except age were evaluated on a categorical scale. Age was evaluated on a linear scale with an additional quadratic term if it showed a non-linear relation to outcome. Because of non-proportional hazards, tested on the basis of Schoenfeld residuals, risk time was split at six months and time-dependent models were estimated to separately evaluate one to six months and six to 48 months after diagnosis of AF. Stratified analysis was conducted for men and women combined with CHA~2~DS~2~-VASc score and age at diagnosis: younger than 65, 65--74 and 75--85 years of age. Unadjusted cumulative risk for cerebral infarction and stroke are visualized in figures for patients with CHA~2~DS~2~-VASc score 1. The same strategy of analysis was employed to evaluate the risk for cerebral bleeding of warfarin treatment but, as no evidence of non-proportional hazard was present, only one period, one to 48 months, was evaluated. Measures of associations were hazard ratios (HR) with 95% confidence intervals (95% CI). Statistical analyses were made using SPSS version 22 (IBM Corp., Armonk, NY, USA) or STATA release 14 (STATA Corp, College Station, TX, USA).

Results {#sec011}
=======

Baseline characteristics {#sec012}
------------------------

The mean age was 71.5 ± 11.4 years. The proportion of women was 44.3% and their mean age was higher than in men, 74.1 ± 9.8 versus 69.5 ± 12.1 years, respectively ([Table 1](#pone.0176846.t001){ref-type="table"}). There were 11 535 patients (23.8% women) \<65 years, 13 157 (27.2%) 65--74 years and 23 741 (49.0%) 75--85 years. Patients with a 0 point on the CHA~2~DS~2~-VASc score were 3 973 (8.2% of all), 1 point 5 934 (12.3%), 2 points 8 289 (17.1%) and ≥3 points 30 237 (62.4%).

Cerebral infarction and stroke {#sec013}
------------------------------

When patients were stratified in groups according to the CHA~2~DS~2~-VASc score (0, 1, 2 and ≥3), age (\<65, 65--74 and 75--85) and sex, those with a point of 0 had no statistically significant benefit of warfarin treatment, HR 0.99 (95% CI 0.54--1.80), while patients with ≥3 points had a beneficial effect in all groups, especially in one to six months of follow-up ([Table 3](#pone.0176846.t003){ref-type="table"}). In the group with 1 point, men between 65 and 74 years had a statistically significant benefit of warfarin treatment, HR 0.46 (95% CI 0.25--0.83), while men and women younger than 65 years had no benefit, with HR 1.11 (95% CI 0.56--2.23) and HR 2.13 (95% CI 0.94--4.82), respectively (Figs [2](#pone.0176846.g002){ref-type="fig"}--[4](#pone.0176846.g004){ref-type="fig"}). In patients with 2 points, there was a statistically significant benefit of warfarin treatment in all groups except in women younger than 65 years with 1 additional point other than sex as a risk factor.

10.1371/journal.pone.0176846.t003

###### Hazard ratios of cerebral infarction and stroke stratified by sex, age and CHA2DS2-VASc score related to time-varying warfarin exposure[^a^](#t003fn002){ref-type="table-fn"}.

![](pone.0176846.t003){#pone.0176846.t003g}

                 Warfarin   No warfarin   1--48 months   1--6 months   6--48 months                                                                                                                                                                                            
  -------------- ---------- ------------- -------------- ------------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  **Men**                                                                                                                                                                                                                                                                      
  **\<65 y**                                                                                                                                                                                                                                                                   
  **0**          1 426      19            2 890          25            0.99 (0.54--1.80)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.92 (0.23--3.70)[^e^](#t003fn006){ref-type="table-fn"}                                             1.09 (0.55--2.16)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **1**          1 141      17            1 228          17            1.11 (0.56--2.23)                                                                                   na                                                                                                  1.07 (0.50--2.33)
  **2**          654        11            695            33            0.35 (0.18--0.69)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.07 (0.01--0.52)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^f^](#t003fn007){ref-type="table-fn"}   0.60 (0.27--1.33)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **≥3**         440        27            443            59            0.37 (0.23--0.59)[^d^](#t003fn005){ref-type="table-fn"}                                             0.27 (0.14--0.52)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.60 (0.28--1.29)[^d^](#t003fn005){ref-type="table-fn"}
  **65--74 y**                                                                                                                                                                                                                                                                 
  **1**          1 004      15            1 240          36            0.46 (0.25--0.83)[^c^](#t003fn004){ref-type="table-fn"}                                             na                                                                                                  0.58 (0.30--1.10)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **2**          1 247      25            1 300          57            0.37 (0.23--0.59)[^d^](#t003fn005){ref-type="table-fn"}                                             0.14 (0.03--0.64)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.43 (0.25--0.72)[^d^](#t003fn005){ref-type="table-fn"}
  **≥3**         1 822      98            2 062          180           0.53 (0.41--0.68)                                                                                   0.30 (0.20--0.47)                                                                                   0.76 (0.54--1.05)
  **75--85 y**                                                                                                                                                                                                                                                                 
  **2**          795        25            1 514          80            0.53 (0.33--0.85)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.40 (0.15--1.07)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   0.59 (0.34--1.01)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **≥3**         3 550      239           6 046          629           0.57 (0.49--0.67)                                                                                   0.38 (0.28--0.52)                                                                                   0.67 (0.56--0.80)
  **Women**                                                                                                                                                                                                                                                                    
  **\<65 y**                                                                                                                                                                                                                                                                   
  **1**          538        10            1 435          12            2.13 (0.94--4.82)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}   1.68 (0.33--8.54)[^e^](#t003fn006){ref-type="table-fn"}^,^ [^f^](#t003fn007){ref-type="table-fn"}   2.31 (0.88--6.06)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **2**          403        15            589            12            1.84 (0.86--3.94)[^d^](#t003fn005){ref-type="table-fn"}                                             na                                                                                                  2.37 (0.97--5.76)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **≥3**         382        14            402            38            0.31 (0.16--0.59)[^d^](#t003fn005){ref-type="table-fn"}                                             0.11(0.03--0.40)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}    0.76 (0.30--1.94)[^f^](#t003fn007){ref-type="table-fn"}
  **65--74 y**                                                                                                                                                                                                                                                                 
  **2**          821        13            1 182          42            0.39 (0.21--0.73)[^c^](#t003fn004){ref-type="table-fn"}                                             na                                                                                                  0.48 (0.25--0.93)[^c^](#t003fn004){ref-type="table-fn"}^,^ [^d^](#t003fn005){ref-type="table-fn"}
  **≥3**         1 948      98            2 039          158           0.58 (0.44--0.75)[^d^](#t003fn005){ref-type="table-fn"}                                             0.36 (0.23--0.56)                                                                                   0.79 (0.55--1.12)
  **75--85 y**                                                                                                                                                                                                                                                                 
  **≥3**         5 096      315           8 777          1 000         0.52 (0.46--0.60)                                                                                   0.45 (0.35--0.57)                                                                                   0.56 (0.48--0.66)

na indicates not applicable, too few events; n, numbers; and y, years of age.

^a^Adjusted for age, year of atrial fibrillation, neoplasm, chronic obstructive pulmonary disease, chronic renal failure and education

^b^Hazard ratio (HR) lower than 1 indicates protective effect of warfarin

^c^Due to sparse data, neoplasm, COPD and chronic renal failure were modeled as one co-morbidity; variable coded as yes/no

^d^Due to sparse data, education level 6--7 aggregated

^e^Due to sparse data, neoplasm, COPD, chronic renal failure and education level excluded

^f^Due to sparse data, education level excluded

![Risk of cerebral infarction and stroke in men 65--74 years of age with atrial fibrillation and one point from the CHA~2~DS~2~-VASc score.](pone.0176846.g002){#pone.0176846.g002}

![Risk of cerebral infarction and stroke in men \<65 years of age with atrial fibrillation and one additional point from the CHA~2~DS~2~-VASc score other than sex or age^a^.\
^a^One additional point indicates congestive heart failure, hypertension, diabetes mellitus or vascular disease.](pone.0176846.g003){#pone.0176846.g003}

![Risk of cerebral infarction and stroke in women \<65 years of age with atrial fibrillation and one point from the CHA2DS2-VASc score.](pone.0176846.g004){#pone.0176846.g004}

There were 18 196 patients with a CHA~2~DS~2~-VASc score of 0, 1, and 2 points at the time of inclusion, and, of those, 5 203 patients that increased their score by ≥1 point from risk factors other than cerebral infarction and stroke during follow-up. We separately analyzed the 12 993 patients whose CHA~2~DS~2~-VASc score remained unchanged at 0, 1 and 2 points during the entire follow-up and found the results to be similar to those of the original cohort ([Table 4](#pone.0176846.t004){ref-type="table"}). The message remained that, in patients with a CHA~2~DS~2~-VASc score of 1, only men 65--74 years of age benefitted from warfarin, together with all patients with 2 points, except women \<65 years old.

10.1371/journal.pone.0176846.t004

###### Hazard ratios of cerebral infarction and stroke in AF patients with an unchanged CHA2DS2-VASc score of 0, 1 and 2 points during the entire study time stratified by sex, age and related to time-varying warfarin exposure[^a^](#t004fn002){ref-type="table-fn"}.

![](pone.0176846.t004){#pone.0176846.t004g}

                 Warfarin   No warfarin   1--48 months   1--6 months   6--48 months                                                                                                                                                                                            
  -------------- ---------- ------------- -------------- ------------- --------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  **Men**                                                                                                                                                                                                                                                                      
  **\<65 y**                                                                                                                                                                                                                                                                   
  **0**          986        15            2 391          20            1.10 (0.55--2.22)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   1.23 (0.27--5.65)[^e^](#t004fn006){ref-type="table-fn"}                                             1.20 (0.55--2.61)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **1**          756        12            887            14            1.15 (0.50--2.65)                                                                                   na                                                                                                  1.24 (0.48--3.20)
  **2**          420        10            477            31            0.37 (0.18--0.77)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   0.07 (0.01--0.59)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^f^](#t004fn007){ref-type="table-fn"}   0.69 (0.29--1.62)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **65--74 y**                                                                                                                                                                                                                                                                 
  **1**          572        7             837            33            0.31 (0.13--0.72)[^c^](#t004fn004){ref-type="table-fn"}                                             na                                                                                                  0.38 (0.16--0.92)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **2**          777        19            898            48            0.43 (0.25--0.73)[^d^](#t004fn005){ref-type="table-fn"}                                             0.19 (0.04--0.85)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^f^](#t004fn007){ref-type="table-fn"}   0.51 (0.28--0.92)[^d^](#t004fn005){ref-type="table-fn"}
  **75--85 y**                                                                                                                                                                                                                                                                 
  **2**          553        21            1 092          71            0.54 (0.33--0.91)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   0.41 (0.14--1.24)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   0.60 (0.34--1.08)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **Women**                                                                                                                                                                                                                                                                    
  **\<65 y**                                                                                                                                                                                                                                                                   
  **1**          314        7             1 105          11            2.06 (0.83--5.09)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   1.97 (0.38--10.1)[^e^](#t004fn006){ref-type="table-fn"}^,^ [^f^](#t004fn007){ref-type="table-fn"}   2.14 (0.69--6.62)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **2**          242        10            411            11            1.48 (0.65--3.33)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}   na                                                                                                  1.97 (0.71--5.45)[^d^](#t004fn005){ref-type="table-fn"}^,^ [^e^](#t004fn006){ref-type="table-fn"}
  **65--74 y**                                                                                                                                                                                                                                                                 
  **2**          465        6             786            30            0.31 (0.13--0.74)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^f^](#t004fn007){ref-type="table-fn"}   na                                                                                                  0.42 (0.17--1.05)[^c^](#t004fn004){ref-type="table-fn"}^,^ [^f^](#t004fn007){ref-type="table-fn"}

na indicates not applicable, too few events; n, numbers; and y, years of age.

^a^Adjusted for age, year of atrial fibrillation, neoplasm, chronic obstructive pulmonary disease, chronic renal failure and education

^b^Hazard ratio (HR) lower than 1 indicates protective effect of warfarin

^c^Due to sparse data, neoplasm, COPD and chronic renal failure were modeled as one co-morbidity; variable coded as yes/no

^d^Due to sparse data, education level 6--7 aggregated

^e^Due to sparse data, neoplasm, COPD, chronic renal failure and education level excluded

^f^Due to sparse data, education level excluded

Cerebral bleeding {#sec014}
-----------------

There was a statistically significant difference between patients with and without warfarin treatment in those with 0 point, where patients with warfarin treatment had an increased risk of cerebral bleeding ([Table 5](#pone.0176846.t005){ref-type="table"}). In patients with 1, 2 and ≥3 points there were no statistically significant differences between those with and without warfarin treatment (Figs [5](#pone.0176846.g005){ref-type="fig"}--[7](#pone.0176846.g007){ref-type="fig"}).

10.1371/journal.pone.0176846.t005

###### Hazard ratios of cerebral bleeding stratified by sex, age and CHA2DS2-VASc score related to time-varying warfarin exposure[^a^](#t005fn002){ref-type="table-fn"}.

![](pone.0176846.t005){#pone.0176846.t005g}

                 Warfarin   No warfarin   1--48 months        
  -------------- ---------- ------------- -------------- ---- ---------------------------------------------------------------------------------------------------
  **Men**                                                     
  **\<65 y**                                                  
  **0**          1 436      10            2 890          4    4.60 (1.40--15.0)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **1**          1 151      12            1 228          9    1.53 (0.62--3.78)[^c^](#t005fn004){ref-type="table-fn"}
  **2**          672        5             695            3    1.64 (0.39--6.92)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **≥3**         472        8             443            6    0.98 (0.33--2.94)[^d^](#t004fn005){ref-type="table-fn"}
  **65--74 y**                                                
  **1**          1 020      11            1 240          11   1.08 (0.46--2.53)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **2**          1 266      16            1 300          13   0.99 (0.47--2.08)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^d^](#t004fn005){ref-type="table-fn"}
  **≥3**         1 874      23            2 062          24   0.83 (0.46--1.48)
  **75--85 y**                                                
  **2**          810        13            1 514          24   0.77 (0.38--1.55)[^d^](#t004fn005){ref-type="table-fn"}
  **≥3**         3 633      58            6 046          94   0.87 (0.62--1.22)
  **Women**                                                   
  **\<65 y**                                                  
  **1**          546        4             1 435          4    2.63 (0.64--10.7)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^e^](#t005fn006){ref-type="table-fn"}
  **2**          410        2             589            4    0.64 (0.12--3.53)[^e^](#t005fn006){ref-type="table-fn"}
  **≥3**         398        6             402            7    1.00 (0.31--3.22)[^e^](#t005fn006){ref-type="table-fn"}^,^ [^f^](#t005fn007){ref-type="table-fn"}
  **65--74 y**                                                
  **2**          847        5             1 182          5    1.31 (0.37--4.61)[^c^](#t005fn004){ref-type="table-fn"}^,^ [^e^](#t005fn006){ref-type="table-fn"}
  **≥3**         2 016      20            2 039          16   1.28 (0.65--2.52)[^d^](#t004fn005){ref-type="table-fn"}^,^ [^f^](#t005fn007){ref-type="table-fn"}
  **75--85 y**                                                
  **≥3**         5 254      54            8 777          95   0.89 (0.63--1.27)[^d^](#t004fn005){ref-type="table-fn"}

na indicates not applicable, too few events; n, numbers and y, years of age.

^a^Adjusted for age, year of atrial fibrillation, neoplasm, chronic obstructive pulmonary disease, chronic renal failure and education

^b^Hazard ratio (HR) lower than 1 indicates protective effect of warfarin

^c^Due to sparse data, neoplasm, COPD and chronic renal failure were modeled as one co-morbidity; variable coded as yes/no

^d^Due to sparse data, education level 5--7 aggregated

^e^Due to sparse data, education level excluded

^f^Due to sparse data, CHA~2~DS~2~-VASc score aggregated 6--9

![Risk of cerebral bleeding in men 65--74 years of age with atrial fibrillation and one point from the CHA~2~DS~2~-VASc score.](pone.0176846.g005){#pone.0176846.g005}

![Risk of cerebral bleeding in men \<65 years of age with atrial fibrillation and one additional point from the CHA~2~DS~2~-VASc score other than sex or age^a^.\
^a^One additional point indicates congestive heart failure, hypertension, diabetes mellitus or vascular disease.](pone.0176846.g006){#pone.0176846.g006}

![Risk of cerebral bleeding in women \<65 years of age with atrial fibrillation and one point from the CHA~2~DS~2~-VASc score.](pone.0176846.g007){#pone.0176846.g007}

Discussion {#sec015}
==========

In this nationwide retrospective cohort study, men and women 65 years and older have a clinically relevant benefit of anticoagulation treatment with warfarin. This also includes otherwise healthy patients, i.e. men with 1 CHA~2~DS~2~-VASc point based on age, and women with 2 points related to age and sex. The prevalence of AF in the population younger than 65 years is 1.2--1.9%; considering the distribution of the total AF population, this corresponds to 18--20% \[[@pone.0176846.ref018],[@pone.0176846.ref020],[@pone.0176846.ref021]\]. This means that approximately 80% of all patients with AF are 65 years or older and might have an indication for treatment with anticoagulants solely based on age as a risk factor.

Risk scores are used to prevent cerebral infarction and stroke while avoiding bleeding complications, and they have different weights on age as a risk factor, from no attention to various points for risks for different age levels \[[@pone.0176846.ref004],[@pone.0176846.ref022]\]. We adopted the recommended score, CHA~2~DS~2~-VASc, which includes age categories \<65, 65--74 and \>75 years giving 0, 1 and 2 points, respectively \[[@pone.0176846.ref004]\]. In all patients that were 65 years and older, we found a beneficial effect of treatment with anticoagulation, and this is in line with earlier findings that an age between 65 and 74 years carries a strong increase in the risk of cerebral infarction and stroke \[[@pone.0176846.ref005],[@pone.0176846.ref008],[@pone.0176846.ref012]\]. In patients younger than 65 years, we found that those with two additional points from risk factors other than age and sex had a beneficial effect of warfarin treatment which is in line with the current ESC guidelines \[[@pone.0176846.ref003]\]. There was consistently no obvious beneficial effect of anticoagulation treatment on cerebral infarction and stroke in men and women younger than 65 years and one additional point other than sex in the CHA~2~DS~2~-VASc, which corresponds to women with two points and men with one point. Men and women younger than 65 years had low stroke rates, and, even with an additional risk score point from a disease, the risk of cerebral infarction and stroke remains too low to confer a benefit of anticoagulation. This is in line with earlier findings that hypertension, vascular disease, diabetes mellitus and heart failure increase the risk of cerebral infarction and stroke but that the impact of only one of these conditions is limited \[[@pone.0176846.ref005],[@pone.0176846.ref012]\]. In patients with ≥3 points, there was a statistically significant positive effect of warfarin treatment during the first six months after the incident AF as compared to 6--48 months, supporting early initiation of an anticoagulant.

Patients with a low CHA~2~DS~2~-VASc score at inclusion may develop comorbidities during follow-up. This happened among 28.5% of the patients with a CHA~2~DS~2~-VASc score of 0, 1 and 2 at inclusion. Since this study focused on the low risk patients, we separately analyzed the risk of cerebral infarction and stroke in patients who remained at risk score 0, 1 and 2 throughout the study ([Table 4](#pone.0176846.t004){ref-type="table"}). The results in the complete cohort remained and, in patients with a CHA~2~DS~2~-VASc score of 1, warfarin was beneficial only in men 65--74 years of age, while all subgroups benefitted in patients with a score of 2, except women \<65 years.

The most severe complication in treatment with warfarin is cerebral bleeding. Our results showed that men younger than 65 years without risk factors and with warfarin treatment had a statistically significantly increased risk of cerebral bleeding. Acetylsalicylic acid in monotherapy shows a similar bleeding risk as warfarin, but the combination increases the risk of bleeding complications and may be a reason for this \[[@pone.0176846.ref003],[@pone.0176846.ref016]\]. However, in all other sub-groups, the risk of cerebral bleeding was equal between patients treated or not treated with warfarin. This is consistent with a recent study and indicates that patients with an equal risk set from the CHA~2~DS~2~-VASc score, irrespective of warfarin, have similar risks of intracranial bleeding \[[@pone.0176846.ref023]\]. Novel oral anticoagulants (NOAC) have shown fewer intracranial bleeding events than warfarin and have been given the same priority as warfarin treatment in the latest guidelines \[[@pone.0176846.ref003]\]. Our study included only patients on warfarin or not on warfarin because NOAC were not available at that time. However, it is likely that these results as concerns warfarin are directly transferable to NOAC and to all patients with non-valvular atrial fibrillation.

The rates of thromboembolic events vary between study populations, meaning that results of treatment are not necessarily comparable between studies. In a low risk population, 50% of the patients with a CHA~2~DS~2~-VASc of 1 point were 65--74 years old and had an almost significant reduction of stroke with warfarin treatment, but the variants of 1 point were not separately analyzed \[[@pone.0176846.ref024]\]. Different definitions of the thromboembolic events can at least partly explain differences in annual stroke rates in the placebo groups \[[@pone.0176846.ref005]--[@pone.0176846.ref011]\]. In comparison, we used as the endpoint cerebral infarction and stroke (I63-I64) and did not include TIA, pulmonary embolus or systemic embolus. We also applied a quarantine period of four weeks to minimize the possibility that the event was not caused by AF, which can have reduced the numbers of endpoints and, finally, we used a time-varying exposure analysis taking into account whether the patients were on active treatment or not.

Age is a risk factor for stroke in several schemes \[[@pone.0176846.ref001]--[@pone.0176846.ref004]\]. However, the cause of the increased risk of stroke due to age is unknown, but may depend on fibrosis, endothelial dysfunction, inflammatory factors and unmeasured co-morbidities \[[@pone.0176846.ref025]\]. There are no methods so far to use biochemical markers in a clinical manner for AF patients, but they may be useful in the future \[[@pone.0176846.ref026]\].

Our findings would have a clinical implication since warfarin is still a common medication. Furthermore, NOAC have shown non-inferiority versus warfarin in preventing thromboembolic events and less intracranial bleeding. For this reason, our results may have relevance when considering any anticoagulant treatment.

Limitations {#sec016}
===========

Our study is retrospective and includes hospitalized patients only, since subjects who are managed entirely out-of-hospital were not included in the registries. We chose to use a strict endpoint for thromboembolic events, i.e. cerebral infarction and stroke based on diagnoses I63 and I64. Inclusion of TIA and other thromboembolic events might have given other results. We do not know the level of underreporting of comorbidities, especially hypertension, a limitation well known from previous studies and which might lead to a misclassification \[[@pone.0176846.ref005], [@pone.0176846.ref006], [@pone.0176846.ref007], [@pone.0176846.ref019], [@pone.0176846.ref023]\]. On the other hand, a strength of this study is the conclusion of an entire population based on a tax-supported health care system that includes a complete follow-up and validation of patient register have shown a high positive predictive value \[[@pone.0176846.ref013]\].

Patients with atrial flutter were included since it often coexists in patients with AF, and the electrocardiographic differentiation between atrial flutter and AF can be challenging. We also chose not to differentiate between paroxysmal and sustained forms of AF, well knowing that the type of AF may have affected the choice of anticoagulant treatment at the time, although this would not be a confounder since the risk of stroke is similar \[[@pone.0176846.ref027]\].

We did not include ASA in the analysis but can not exclude some influence, although studies on ASA and AF did not show any positive or negative effects in the rates of cerebral infarction or cerebral bleeding \[[@pone.0176846.ref003], [@pone.0176846.ref015], [@pone.0176846.ref016]\]. Finally, we have no data on the time within the therapeutic range of warfarin treatment, but studies indicate that anticoagulation control in Sweden is satisfactory \[[@pone.0176846.ref028]\].

Conclusions {#sec017}
===========

The results of this retrospective study based on hospitalized patients support that warfarin may be considered in all patients with AF and an age of 65 years and older, i.e. also when the CHA~2~DS~2~-VASc score is 1. Our results also support that warfarin is beneficial in patients \<65 years of age in men with CHA~2~DS~2~-VASc score ≥2 and in women ≥3 points. In addition, there were no increased risks of cerebral bleeding in these patients.
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